Área Sanitaria da Coruña e Cee
Sanitary area
Pfizer (United States)
Nueva York, Estados UnidosPublications in collaboration with researchers from Pfizer (United States) (47)
2024
-
Clinical Outcomes of Enzalutamide in Metastatic Hormone-sensitive Prostate Cancer in Patients Aged <75 and ≥75 Years: ARCHES Post Hoc Analysis
European urology oncology, Vol. 7, Núm. 4, pp. 860-869
-
Effect of long-term tafamidis treatment on health-related quality of life in patients with transthyretin amyloid cardiomyopathy
European Journal of Heart Failure, Vol. 26, Núm. 3, pp. 612-615
-
Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer
Clinical Drug Investigation, Vol. 44, Núm. 8, pp. 553-576
-
Prevalence and characteristics of transthyretin amyloid cardiomyopathy in hypertrophic cardiomyopathy
ESC Heart Failure
-
REALM-DCM: A Phase 3, Multinational, Randomized, Placebo-Controlled Trial of ARRY-371797 in Patients With Symptomatic LMNARelated Dilated Cardiomyopathy
Circulation: Heart Failure, Vol. 17, Núm. 7, pp. e011548
-
The effect of long-term tafamidis treatment on quality of life in people with transthyretin amyloid cardiomyopathy (ATTR-CM): A plain language summary
Future Cardiology
2023
-
Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations
Journal of Thoracic Oncology, Vol. 18, Núm. 11, pp. 1581-1593
-
Etanercept Withdrawal and Retreatment in Nonradiographic Axial Spondyloarthritis: Results of RE-EMBARK, an Open-Label Phase IV Trial
Journal of Rheumatology, Vol. 50, Núm. 4, pp. 478-487
-
The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES
European Urology, Vol. 84, Núm. 2, pp. 229-241
2022
-
Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk
Prostate Cancer and Prostatic Diseases, Vol. 25, Núm. 2, pp. 274-282
-
Improved Survival with Enzalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer
Journal of Clinical Oncology, Vol. 37
-
Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study
European Journal of Cancer, Vol. 168, pp. 12-24
-
Response to: 'Use of tanezumab for patients with hip and knee osteoarthritis with reference to a randomised clinical trial by Berenbaum and colleagues' by Riddle and Perera
Annals of the Rheumatic Diseases
-
The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups
Prostate, Vol. 82, Núm. 13, pp. 1237-1247
2021
-
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
Autophagy, Vol. 17, Núm. 1, pp. 1-382
-
Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor–positive metastatic breast cancer: Patient-reported outcomes in the PEARL study
European Journal of Cancer, Vol. 156, pp. 70-82
-
Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study
The Lancet Oncology, Vol. 22, Núm. 2, pp. 212-222
-
Patient Journey in Atopic Dermatitis: The Real-World Scenario
Dermatology and Therapy, Vol. 11, Núm. 5, pp. 1693-1705
-
Subcutaneous tanezumab for osteoarthritis: Is the early improvement in pain and function meaningful and sustained?
European Journal of Pain (United Kingdom), Vol. 25, Núm. 7, pp. 1525-1539
2020
-
Cost-effectiveness analysis of second-line pharmacological treatment of acromegaly in Spain
Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 20, Núm. 1, pp. 105-114